← #events

Hollandbio Year Event 2025

Hollandbio

30/01/25


It’s time again for hollandbio’s Year Event—the top gathering in the Netherlands celebrating biotech’s power and potential. This is also the moment to thank our members and partners in this thriving ecosystem. Join us on Thursday, January 30th, at Theatre Flint in Amersfoort! 

Whether you’re a regular attendee or joining us for the first time, this event offers the perfect opportunity to connect with familiar faces and new contacts alike. Expect an afternoon filled with inspiring keynotes and insights into the future of biotech, a healthy dose of humor and plenty of networking opportunities

Practical information 

  • Date: Thursday, January 30th 2025 
  • Duration: 15:00 – 22:00 hrs 

Programme

  • 15.00 – 15.30     Start of registration
  • 15.30 – 15.40     Welcome – Annemiek Verkamman, Managing Director Hollandbio
  • 15.40 – 16.15     Keynote 1: Edwin Moses, Independent Board Director
  • 16.15 – 16.50     Keynote 2: Björn Heijstra, VP Commercial Innovation at LanzaTech
  • 16.50 – 17.00    Closing – Annemiek Verkamman, Managing Director Hollandbio

And of course there will be drinks, dinner, music & networking after the plenary programme.

Registration 

The hollandbio Year Event welcomes  hollandbio members  (up to 4 representatives per organization) and stakeholders by invitation only. Registration can be done through the the ‘Get your ticket’ button on the top right.

Would you like to join, but have not received an invitation? Or are you interested in a  hollandbio membership? Then feel free to get in touch! 

Björn Heijstra, VP Commercial Innovation at LanzaTech: The LanzaTech scaleup story

Björn has been involved with LanzaTech since the company’s inception in New Zealand, contributing to its growth in various roles. Combining expertise in synthetic biology, bioinformatics, artificial intelligence, and machine learning with engineering, LanzaTech has developed a platform that converts waste carbon into new everyday products that would otherwise rely on virgin fossil resources. LanzaTech’s carbon recycling gas fermentation technology has been commercially operational in China since 2018. The process can be likened to retrofitting a brewery onto an emissions source, such as a steel mill or landfill, but instead of using sugars and yeast to brew beer, industrial emissions (carbon oxides like CO, CO2, and H2) are converted by bacteria into fuels and chemicals.

The primary product, ethanol, is already used in Europe in consumer products under the brand name CarbonSmart. For example, ethanol is being developed for household cleaning products in collaboration with Mibelle in Switzerland. LanzaTech’s technology enables the sustainable production of a variety of chemicals for use in textiles, sneakers, perfumes, or even aviation fuel, to name just a few.

After 15+ years at LanzaTech, Björn will summarize the scaleup journey from a New Zealand basement laboratory to global commercial deployment.

Edwin Moses, Independent Board Director: Highs and lows from a life in biotech, one of the most fulfilling environments you could ever hope to work in.

Dr. Edwin Moses has a Ph.D. in Chemistry from the University of Sheffield (UK) and a Post-Doctoral Fellowship in Biophysical Chemistry from the University of Regensburg (Germany). Edwin Moses is a serial entrepreneur and value creator in European life science companies. As CEO, he built two businesses (Ablynx NV and Oxford Asymmetry International), led their successful IPOs on the LSE, EuroNext and NASDAQ, and raised over €500 million in equity and debt financing. Mr. Moses oversaw multiple deal-making at Ablynx which generated ~€0.5 billion in cash, >€10 billion in potential milestones plus royalties. He was responsible for developing the business plans and implementing them. He has expertise in high-value service provision to the pharmaceutical industry and drug discovery and development. His primary focus is on high-growth businesses and change management. Mr. Moses has 25 years of board-level experience in more than 10 companies, mostly as Chairman.